IL320004A - Methods for treating estrogen receptor-mediated disorders - Google Patents
Methods for treating estrogen receptor-mediated disordersInfo
- Publication number
- IL320004A IL320004A IL320004A IL32000425A IL320004A IL 320004 A IL320004 A IL 320004A IL 320004 A IL320004 A IL 320004A IL 32000425 A IL32000425 A IL 32000425A IL 320004 A IL320004 A IL 320004A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- kit
- pharmaceutically acceptable
- acceptable salt
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (32)
1. A method of treating an estrogen receptor mediated disease, disorder, or condition in a subject comprising administering a composition comprising Compound or a pharmaceutically acceptable salt thereof, wherein Compound 1 is administered in an amount that is about 15 mg to about 360 mg, in combination with a composition comprising about 200 to about 800 mg of ribociclib, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein Compound 1 is administered in an amount that is about 30 mg to about 120 mg.
3. The method of claim 1 or 2, wherein Compound 1 is administered in an amount that is about 30 mg.
4. The method of claim 1 or 2, wherein Compound 1 is administered in an amount that is about 60 mg.
5. The method of claim 1 or 2, wherein Compound 1 is administered in an amount that is about 90 mg.
6. The method of claim 1 or 2, wherein Compound 1 is administered in an amount that is about 120 mg.
7. The method of any one of claims 1-6, wherein ribociclib is administered in an amount that is about 500 to about 700 mg.
8. The method of any one of claims 1-7, wherein ribociclib is administered in an amount that is about 600 mg.
9. The method of any one of claims 1-8, wherein Compound 1 is administered once daily.
10. The method of any one of claims 1-8, wherein ribociclib is administered once daily for 21 days, followed by a 7-day dose holiday.
11. The method of any one of claims 1-10, wherein Compound 1 and ribociclib are administered concomitantly.
12. The method of any one of claims 1-11, wherein the composition comprising Compound 1 or a pharmaceutically acceptable salt thereof is a capsule or a tablet.
13. The method of claim 12, wherein the composition comprising ribociclib or a pharmaceutically acceptable salt thereof is a capsule or a tablet.
14. The method of any one of claims 1-13, wherein the estrogen receptor-mediated disease, disorder, or condition is a cancer.
15. The method of claim 14, wherein the cancer is breast cancer.
16. The method of claim 15, wherein the cancer is HR+/HER2- breast cancer.
17. The method of any one of claims 14-16, wherein the cancer has metastasized to another organ.
18. The method of claim 17, wherein the cancer has metastasized to the brain, bone, lungs, or liver.
19. The method of any one of claims 1-18, wherein the subject has previously received at least one of a CDK4/6 inhibitor, an aromatase inhibitor, chemotherapy, fulvestrant, or a combination thereof.
20. In a method of treating a disease, disorder, or condition comprising administering Compound , or a pharmaceutically acceptable salt thereof, and ribociclib in combination, the improvement comprising administering from about 30 mg to about 120 mg Compound 1, or a pharmaceutically acceptable salt thereof, and about 600 mg of ribociclib, or a pharmaceutically acceptable salt thereof.
21. A kit comprising a composition comprising about 30 mg to about 360 mg of Compound 1 or a pharmaceutically acceptable salt thereof, and a composition comprising about 200 to about 800 mg of ribociclib, or a pharmaceutically acceptable salt thereof.
22. The kit of claim 21, wherein the kit comprises about 30 mg of Compound 1, or a pharmaceutically acceptable salt thereof.
23. The kit of claim 21, wherein the kit comprises about 60 mg of Compound 1, or a pharmaceutically acceptable salt thereof.
24. The kit of claim 21, wherein the kit comprises about 90 mg of Compound 1, or a pharmaceutically acceptable salt thereof.
25. The kit of claim 21, wherein the kit comprises about 120 mg of Compound 1, or a pharmaceutically acceptable salt thereof.
26. The kit of any one of claims 21-25, wherein the kit comprises about 600 mg of ribociclib, or a pharmaceutically acceptable salt thereof.
27. The kit of any one of claims 21-26, wherein the kit further comprises packaging material that comprises a label which indicates that Compound 1 and ribociclib can be used for treating an estrogen-receptor mediated disease, disorder, or condition.
28. The kit of claim 27, wherein the estrogen receptor-mediated disease, disorder, or condition is a cancer.
29. The kit of claim 28, wherein the cancer is breast cancer.
30. The kit of claim 29, wherein the cancer is HR+/HER2- breast cancer.
31. The kit of any one of claims 28-30, wherein the cancer has metastasized to another organ.
32. The kit of claim 31, wherein the cancer has metastasized to the brain, bone, lungs, or liver. For the Applicant WOLFF, BREGMAN AND GOLLER By:
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263413475P | 2022-10-05 | 2022-10-05 | |
| PCT/US2023/034454 WO2024076626A1 (en) | 2022-10-05 | 2023-10-04 | Methods of treating estrogen receptor-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320004A true IL320004A (en) | 2025-06-01 |
Family
ID=90608897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320004A IL320004A (en) | 2022-10-05 | 2023-10-04 | Methods for treating estrogen receptor-mediated disorders |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4598520A1 (en) |
| JP (1) | JP2025533900A (en) |
| KR (1) | KR20250095627A (en) |
| CN (1) | CN120187424A (en) |
| AU (1) | AU2023356291A1 (en) |
| IL (1) | IL320004A (en) |
| MX (1) | MX2025004050A (en) |
| WO (1) | WO2024076626A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138659A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| EP2434891B9 (en) * | 2009-05-27 | 2021-05-05 | PTC Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| EP3355884B1 (en) * | 2015-10-01 | 2021-04-28 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
| CN113490850B (en) * | 2018-08-17 | 2024-12-06 | 基因泰克公司 | Diagnostic and therapeutic approaches used to treat breast cancer |
| WO2021178846A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
-
2023
- 2023-10-04 IL IL320004A patent/IL320004A/en unknown
- 2023-10-04 WO PCT/US2023/034454 patent/WO2024076626A1/en not_active Ceased
- 2023-10-04 CN CN202380071326.0A patent/CN120187424A/en active Pending
- 2023-10-04 JP JP2025520010A patent/JP2025533900A/en active Pending
- 2023-10-04 EP EP23875477.4A patent/EP4598520A1/en active Pending
- 2023-10-04 AU AU2023356291A patent/AU2023356291A1/en active Pending
- 2023-10-04 KR KR1020257014629A patent/KR20250095627A/en active Pending
-
2025
- 2025-04-04 MX MX2025004050A patent/MX2025004050A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN120187424A (en) | 2025-06-20 |
| MX2025004050A (en) | 2025-05-02 |
| EP4598520A1 (en) | 2025-08-13 |
| AU2023356291A1 (en) | 2025-04-17 |
| JP2025533900A (en) | 2025-10-09 |
| KR20250095627A (en) | 2025-06-26 |
| WO2024076626A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10765684B2 (en) | Reduction of side effects from aromatase inhibitors used for treating breast cancer | |
| Fan et al. | PERK, beyond an unfolded protein response sensor in estrogen-induced apoptosis in endocrine-resistant breast cancer | |
| RU2018133298A (en) | WAYS OF APPLICATION OF FXR AGONISTS | |
| US8853188B2 (en) | Compositions and methods for cancer treatment | |
| WO2008004798A8 (en) | Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | |
| IL320452A (en) | Combination therapy for prostate cancer | |
| US20160113925A1 (en) | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors | |
| US20110190244A1 (en) | Method of treatment of egfr inhibitor toxicity | |
| CN109562080A (en) | Pharmaceutical compositions for the treatment of cancer and cancer complications | |
| RU2004137801A (en) | COMPOSITION FOR CANCER THERAPY BY SAPONINES OR SAPOGENINS | |
| IL320004A (en) | Methods for treating estrogen receptor-mediated disorders | |
| CN102441168B (en) | Pharmaceutical composition containing apigenin, apigenin derivatives and Bcl-2 inhibitor and its application in preparation of medicine for treating cancer | |
| JPWO2008139952A1 (en) | Microtubule disrupting agent and cancer cell growth inhibitor containing the same | |
| Guo et al. | Estrogen Receptor α (ERα)-targeting compounds and derivatives: Recent advances in structural modification and bioactivity | |
| RU2025111136A (en) | TREATMENT METHODS FOR ESTROGEN RECEPTOR-MEDIATED DISORDERS | |
| RU2010140888A (en) | IMPROVED ANTI-CANCER THERAPIES | |
| MXPA04005771A (en) | Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances. | |
| WO2020175922A3 (en) | Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia | |
| US20240366562A1 (en) | Gynecomastia and/or mastalgia treatment | |
| TW200902028A (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases | |
| CN117956986A (en) | Gynecomastia and/or mastalgia treatment | |
| AU2012200290B2 (en) | Reduction of side effects from aromatase inhibitors used for treating breast cancer | |
| US9907797B2 (en) | Combination therapies for overcoming resistance to mitotic agents during chemotherapy | |
| AU2006303878B2 (en) | Reduction of side effects from aromatase inhibitors used for treating breast cancer | |
| Starr | PACIFIC: Practice-Changing Study in Stage III Unresectable Non-Small-Cell Lung Cancer. |